tirzepatide and hormone replacement therapy New research from a Mayo Clinic–led study suggests that postmenopausal women using menopause may experience greater weight loss when treated with tirzepatide, a GLP-1–based medication for overweight obesity. In New study links combination of

Evidence boundary The largest Phase 2b trial used oral dosing for 24 weeks and did not show statistically significant weight loss versus placebo

When the stomach retains food for longer periods, there may be increased gastric distension and pressure, which could exacerbate reflux symptoms or discomfort in susceptible individuals

Also, the therapy helps to reach nutrients to the body cells for an overall immunity boost

Seek urgent care for signs of allergy such as swelling, hives, or breathing difficulty

2C) levels were higher than the corresponding preintervention values (p = 0.040 and p = 0.042, respectively)

Ozempic and Mounjaro are currently only indicated for diabetes